2CB-5OCD3

2CB-5OCD 3 , also known as 5-trideuteromethoxy-2C-B, is a serotonin 5-HT 2A receptor agonist and possible psychedelic drug of the phenethylamine and 2C families.

Uses your system voice; voice and rate in settings.

Snapshot

≈ 1 min read

Names in other languages

No names in other languages are held for this entry yet.

Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.

2CB-5OCD 3 , also known as 5-trideuteromethoxy-2C-B, is a serotonin 5-HT 2A receptor agonist and possible psychedelic drug of the phenethylamine and 2C families. It is the isotopologue of 2C-B in which the three hydrogen atoms of the methoxy group at the 5 position have been replaced with the deuterium isotopes.

The drug shows similar serotonin 5-HT 2A receptor pharmacodynamics and metabolism as 2C-B in vitro. The chemical synthesis of 2CB-5OCD 3 has been described. 2CB-5OCD 3 was developed by Nicholas V. Cozzi and Paul F. Daley of the Alexander Shulgin Research Institute (ASRI).

It was patented in 2024 and was first described in the scientific literature in 2026.

Text derived from https://en.wikipedia.org/w/index.php?oldid=1360398183 under CC BY-SA 4.0; modifications have been made.

Sources cited in this revision

1 named source(s) extracted from the cited revision. A source with no author is shown by its publication; nothing is invented.